Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis

Veterinary Immunology and Immunopathology

Volumn 141, Issue 1-2, 2011, Pages 64-75

  Araújo, Márcio Sobreira Silva ^a   de Andrade, Renata Aline ^a   Sathler Avelar, Renato ^a   Magalhães, Camila Paula ^a   Carvalho, Andréa Teixeira ^a   Andrade, Mariléia Chaves ^a,f   Campolina, Sabrina Sidney ^a   Mello, Maria Norma ^b   Vianna, Leonardo Rocha ^c   Mayrink, Wilson ^b   Reis, Alexandre Barbosa ^d   Malaquias, Luiz Cosme Cotta ^e   Rocha, Luciana Morais ^a   Martins Filho, Olindo Assis ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c PMMG ^*  (Brazil)

^d FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^e FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

^f CCBS   (Brazil)

Author keywords

Cytokines; Immunophenotyping; Leishmaniasis canine; Leishmune ; Leishvaccine; Nitric oxide

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 4; LEISHMUNE; LEISHVACCINE; NITRIC OXIDE; PROTOZOAL VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BIOCHEMISTRY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG MECHANISM; EOSINOPHIL; FEMALE; IMMUNIZATION; IN VITRO STUDY; INFECTION PREVENTION; INNATE IMMUNITY; LEUKOCYTE; MALE; NEUTROPHIL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; T LYMPHOCYTE ACTIVATION; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, PROTOZOAN; CYTOKINES; DOG DISEASES; DOGS; FEMALE; IMMUNITY, INNATE; LEISHMANIA INFANTUM; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; LEUKOCYTES; MALE; NITRIC OXIDE SYNTHASE;

CANIS FAMILIARIS; MYCOBACTERIUM BOVIS BCG;

EID: 79953657116     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2011.02.007     Document Type: Article

References (47)

1. Abranches P., Silva-Pereira M.C., Conceição-Silva F.M., Santos-Gomes G.M., Janz J.G. Canine leishmaniasis: pathological and ecological factors influencing transmission of infection. J. Parasitol. 1991, 77(4):557-561.
2. Aguilar-Torrentera F., Carlier Y. Immunological factors governing resistance and susceptibility of mice to Leishmania major infection. Rev. Latinoam Microbiol. 2001, 43(3):135-142.
3. Aucouturier J., Dupuis L., Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001, 21(19 (17-19)):2666-2672.
4. Baneth G., Shaw E. Chemotherapy of canine leishmanioses. Vet. Parasitol. 2002, 106:315-324.
5. Barbiéri C.L. Immunology of canine leishmaniasis. Parasite Immunol. 2006, 28(7):329-337.
6. Borja-Cabrera G.P., Cruz Mendes A., Paraguai de Souza E., Hashimoto Okada L.Y., De ATrivellato F.A., Kawasaki J.K., Costa A.C., Reis A.B., Genaro O., Batista L.M., Palatnik M., Palatnik-de-Sousa C.B. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 2004, 2(22 (17-18)):2234-2243.
7. Brachelente C., Muller N., Doherr M.G., Sattler U., Welle M. Cutaneous leishmaniasis in naturally infected dogs is associated with a T helper-2-biased immune response. Vet. Pathol. 2005, 42:166-175.
8. Brossart P., Bevan M.J. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 1997, 90:1594-1599.
9. Barclay A.N., Brown M.H., Law S.K.A., McKnight A.J. The Leucocyte Antigen Facts Book 1997, Academic Press, 613pp. 2nd ed.
10. Camargo E.P. Growth and differentiation in Trypanosoma cruzi. I. Origin of metacyclic trypanosomes in liquid media. Rev. Inst. Med. Trop. São Paulo 1964, 6:93-100.
11. Carrillo E., Moreno J. Cytokine profiles in canine visceral leishmaniasis. Vet. Immunol. Immunopathol. 2009, 15(128 (1-3)):67-70.
12. Cobbold S., Metcalfe S. Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW). Tissue Antigens 1994, 43(3):137-154.
13. da Costa C.A., Afonso L.C., Toledo V.P., Guimaraes T.M., Nascimento E., Tavares C.A., Mayrink W. Immune responses and protection induced in mice by an industrialized vaccine against American cutaneous leishmaniasis. Parassitologia 1992, 34(1-3):45-51.
14. Dantas-Torres F. Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine. Vet. Parasitol. 2006, 141:1-8.
15. Fujiwara R.T., Bueno L.L., Vale A.M., Franca-Silva J.C., da Costa R.T., Quetz J.S., Machado-Coelho G.L., Reis A.B., Martins Filho O.A., Genaro O., Nascimento E., Mayrink W. Flow cytometric assay in peripheral blood of dogs-reference values for leukocytes from Brazilian beagles. Pol. J. Vet. Sci. 2005, 8(1):17-22.
16. Giunchetti R.C., Corrêa-Oliveira R., Martins-Filho O.A., Teixeira-Carvalho A., Roatt B.M., de Oliveira Aguiar-Soares R.D., de Souza J.V., das Dores Moreira N., Malaquias L.C., Mota e Castro L.L., de Lana M., Reis A.B. Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs. Vaccine 2007, 25(44):7674-7686.
17. Giunchetti R.C., Reis A.B., da Silveira-Lemos D., Martins-Filho O.A., Corrêa-Oliveira R., Bethony J., Vale A.M., da Silva Quetz J., Bueno L.L., França-Silva J.C., Nascimento E., Mayrink W., Fujiwara R.T. Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis. Res. Vet. Sci. 2008, 85(1):106-112.
18. Giunchetti R.C., Corrêa-Oliveira R., Martins-Filho O.A., Teixeira-Carvalho A., Roatt B.M., de Oliveira Aguiar-Soares R.D., Coura-Vital W., de Abreu R.T., Malaquias L.C., Gontijo N.F., Brodskyn C., de Oliveira C.I., Costa D.J., de Lana M., Reis A.B. A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs. Vaccine 2008, 26(5):623-638.
19. Gradoni L. An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet. Parasitol. 2001, 100:87-103.
20. , rapid method for determining nitrates and nitrites in biological fluids. Clin. Chem. 1992, 38(10):2152.
21. Houde M., Bertholet S., Gagnon E., Brunet S., Goyette G., Laplante A., Princiotta M.F., Thibault P., Sacks D., Desjardins M. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003, 25(425 (6956)):402-406.
22. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5(10):987-995.
23. Kemp K., Kemp M., Kharazmi A., Kurtzhals J.A.L., Theander T.G. Leishmania-specific T cells expressing interfern-gamma (IFN-g) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin. Exp. Immunol. 1999, 116:500-504.
24. Kensil C.R. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst. 1996, 13(1-2):1-55.
25. Lalor M.K., Smith S.G., Floyd S., Gorak-Stolinska P., Weir R.E., Blitz R., Branson K., Fine P.E., Dockrell H.M. Complex cytokine profiles induced by BCG vaccination in UK infants. Vaccine 2010, 10(28 (6)):1635-1641.
26. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
27. Mayrink W., Genaro O., França-Silva J.C., Da Costa R.T., Tafuri W.L., Rotondo A., Reis A.B., Williams P., Costa C.A. Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs. Mem. Inst. Oswaldo Cruz. 1996, 80(6):695-697.
28. Mayrink W., Santos G.C., Toledo V., de P., Guimaraes T.M., Machado-Coelho G.L., Genaro O., da Costa C.A. Vaccination of C57BL/10 mice against cutaneous Leishmaniasis using killed promastigotes of different strains and species of Leishmania. Rev. Soc. Bras. Med. Trop. 2002, 35(2):125-132.
29. McFarlane E., Perez C., Charmoy M., Allenbach C., Carter K.C., Alexander J., Tacchini-Cottier F. Neutrophils contribute to development of a protective immune response during onset of infection with Leishmania donovani. Infect. Immun. 2008, 76(2):532-541.
30. Moore P.F., Rossitto P.V., Danilenko D.M., Wielenga J.J., Raff R.F., Severns E. Monoclonal antibodies specific for canine CD4 and CD8 define functional T-lymphocyte subsets and high-density expression of CD4 by canine neutrophils. Tissue Antigens 1992, 40(2):75-85.
31. Moreno J., Alvar J. Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol. 2002, 18(9):399-405.
32. Noli C., Auxilia S.T. Treatment of canine Old World visceral leishmaniasis: a systematic review. Vet. Dermatol. 2005, 16:213-232.
33. Palatnik de Sousa C.B., Santos W.R., França-Silva J.C., Costa R.T., Reis A.B., Palatnick M., Mayrink W., Genaro O. Impact of canine control in the epidemiology of canine and human visceral leishmaniasis in Brazil. Am. J. Trop. Med. Hyg. 2001, 65(5):510-517.
34. Palatnik-de-Sousa C.B. Vaccines for leishmaniasis in the fore coming 25years. Vaccine 2008, 26:1709-1724.
35. Panaro M.A., Acquafredda A., Lisi S., Lofrumento D.D., Mitolo V., Sisto M., Fasanella A., Trotta T., Bertani F., Consenti B., Brandonisio O. Nitric oxide production by macrophages of dogs vaccinated with killed Leishmania infantum promastigotes. Comp. Immunol. Microbiol. Infect. Dis. 2001, 24:187-195.
36. Pinelli E., Boog C.J., Rutten V.P., Van Dijk B., Bernadina W.E., Ruitenberg E.J. A canine CD8+ cytotoxic T-cell line specific for Leishmania infantum-infected macrophages. Tissue Antigens 1994, 43(3):189-192.
37. Pinelli E., Gebhard D., Mommaas A.M., van Hoeij M., Langermans J.A., Ruitenberg E.J., Rutten V.P. Infection of a canine macrophage cell line with Leishmania infantum: determination of nitric oxide production and anti-leishmanial activity. Vet. Parasitol. 2000, 1(92 (3)):181-189.
38. Quinnell R.J., Courtenay O., Shaw M.A., Day M.J., Garcez L.M., Dye C., Kaye P.M. Tissue cytokine responses in canine visceral leishmaniasis. J. Infect Dis. 2001, 183(9):1421-1424.
39. Rajput Z.I., Hu S.H., Xiao C.W., Arijo A.G. Adjuvant effects of saponins on animal immune responses. J. Zhejiang Univ. Sci. B. 2007, 8(3):153-161.
40. Reis A.B., Carneiro C.M., Carvalho M.G., Teixeira-Carvalho A., Giunchetti R.C., Mayrink W., Genaro O., Corrêa-Oliveira R., Martins-Filho O.A. Establishment of a microplate assay for flow cytometric assessment and it is use for the evaluation of age-related phenotypic changes in canine whole blood leukocytes. Vet. Immunol. Immunopathol. 2005, 103(3-4):173-185.
41. Reis A.B., Giunchetti R.C., Carrillo E., Martins-Filho O.A., Moreno J. Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis. Trends Parasitol. 2010, 26(7):341-349.
42. Rousseau D., Demartino S., Ferrua B., Michiels J.F., Anjuère F., Fragaki K., Le Fichoux Y., Kubar J. In vivo involvement of polymorphonuclear neutrophils in Leishmania infantum infection. BMC Microbiol. 2001, 1:17.
43. Scott M.T., Goss-Sampson M., Bomford R. Adjuvant activity of saponina: antigen localization studies. Int. Arch. Allergy Appl. Immunol. 1985, 77:409-412.
44. Tesh R.B. Control of zoonotic visceral leishmaniasis: is it time to change strategies?. Am. J. Trop. Med. Hyg. 1995, 52:287-292.
45. Vanloubbeeck Y., Jones D.E. The immunology of Leishmania infection and the implications for vaccine development. Ann. NY Acad. Sci. 2004, 1026:267-272.
46. Vouldoukis I., Bécherel P.A., Riveros-Moreno V., Arock M., da Silva O., Debré P., Mazier D., Mossalayi M.D. Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur. J. Immunol. 1997, 27(4):860-865.
47. Xing Z., Charters T.J. Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis. Exp. Rev. Vaccine 2007, 6(4):539-546.